


**AROG4-01: A High-Impact
Oncology Investment Opportunity
Specific and incisive mechanism
of action for the treatment of
resistant cancers**



Executive Summary

Cancer remains one of the leading causes of mortality worldwide. Aggressive tumors and resistance to conventional treatments limit the success of current therapies, creating an urgent need for disruptive innovations in oncology. The market demands new solutions capable of overcoming tumor escape mechanisms and significantly improving therapeutic outcomes.

A Disruptive Innovation in Precision Oncology

AROG4-01 is a next-generation therapy designed to change the paradigm in oncology. Unlike traditional therapies that act on already-formed proteins, AROG4-01 prevents the production of key cancer-driving proteins before they are generated. This approach stops tumor growth at its source and minimizes the risk of drug resistance. By targeting non-canonical structures within RNA, AROG4-01 offers a highly specific mechanism to selectively inhibit the translation of oncogenic proteins without affecting normal cellular processes.

Key Advantages of AROG4-01

AROG4-01 represents a breakthrough in cancer treatment through its unique mechanism of action. By inhibiting the production of oncogenic proteins at the RNA level, it prevents tumor progression more effectively than traditional therapies. Additionally, its design avoids tumor adaptation, a major cause of treatment failure. Preclinical studies have demonstrated significant tumor reduction in lung, ovarian, and colorectal cancer models, validating its therapeutic potential.

Investment Opportunity: High-Value, De-Risked Entry

AROG4-01 is currently raising a €10M Series A round to fund its first-in-human clinical trial (Phase I), evaluating safety, pharmacokinetics, and preliminary efficacy. The trial will also include biomarker analysis to optimize patient selection for future Phase II trials.

Funding Status & Use of funds. To date, €2M has been secured through grants from the Spanish Government (CDTI). The remaining funds will support regulatory approvals, clinical trials, and strategic partnerships. The Phase I clinical trial is scheduled to start in April 2025 and will be conducted in two stages: a dose escalation phase with 18 patients with refractory solid tumors, aimed at defining safety and pharmacokinetic profiles, followed by an expansion phase with 40 additional patients to confirm safety and gather preliminary efficacy data. The total investment required to complete the study is €10M, with €3M allocated for the first phase and €7M for the second.

Market Potential & Competitive Edge

The global RNA-targeting oncology market is rapidly growing and is expected to reach €5Billion by 2030. AROG4-01 is positioned within this expanding segment, offering a differentiated approach compared to other RNA-targeted therapies. While many competitors focus on RNA degradation, AROG4-01 leverages an innovative strategy based on translation regulation, opening new opportunities in precision oncology.

Projected Valuation Growth & Exit Strategies

The valuation of oncology assets increases significantly as they progress through clinical development. Investors entering this phase can anticipate substantial value growth:

- Preclinical (GLP completed): €10-20M
- IND approval (Phase I start): €40-50M
- Phase I completion: €100M+
- Phase II completion: €200-500M+
- Pharma Licensing & M&A: Recent RNA therapy licensing deals range from €200M upfront to €600M+ in milestone payments.

Investment Models & Potential Returns

We are open to discussing different investment structures to align with strategic investor objectives:

- Direct Equity Investment – Participate in the Series A round with a potential 5-10x valuation increase post-Phase II.
- Convertible Loan – Equity conversion at a discount upon reaching the next valuation milestone (IND or Phase I completion).
- Licensing/M&A – Potential acquisition by a pharmaceutical company, offering 3-5x ROI upon Phase II completion.
- Market Exclusivity – Investors can secure exclusive commercialization rights in Saudi Arabia and the MENA region, creating a revenue-generating biotech asset.

Why Invest Now?

AROG4-01 presents a unique opportunity in a rapidly expanding market with high demand for innovation in oncology. Its unique mechanism of action, expansion potential into additional indications, and strong preclinical validation make it a compelling investment with mitigated risk and high return potential.

Join Us in Transforming Cancer Therapy

For more information, contact:

Dr. Carmen Plasencia, CEO

Email: carme.plasencia@aromics.es | Website: www.aromics.es